Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations by Gilsbach, Bernd K. et al.
  
 University of Groningen
Roco kinase structures give insights into the mechanism of Parkinson disease-related
leucine-rich-repeat kinase 2 mutations
Gilsbach, Bernd K.; Ho, Franz Y.; Vetter, Ingrid R.; van Haastert, Peter J. M.; Wittinghofer,
Alfred; Kortholt, Arjan
Published in:
Proceedings of the National Academy of Sciences of the United States of America
DOI:
10.1073/pnas.1203223109
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2012
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Gilsbach, B. K., Ho, F. Y., Vetter, I. R., van Haastert, P. J. M., Wittinghofer, A., & Kortholt, A. (2012). Roco
kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase
2 mutations. Proceedings of the National Academy of Sciences of the United States of America, 109(26),
10322-10327. https://doi.org/10.1073/pnas.1203223109
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Roco kinase structures give insights into the
mechanism of Parkinson disease-related
leucine-rich-repeat kinase 2 mutations
Bernd K. Gilsbacha,b, Franz Y. Hoc, Ingrid R. Vetterb, Peter J. M. van Haasterta, Alfred Wittinghoferb,1,
and Arjan Kortholta,b,1
aDepartment of Cell Biochemistry, University of Groningen, 9747 AG, Groningen, The Netherlands; bStructural Biology Group, Max Planck Institut für
Molekulare Physiologie, 44227 Dortmund, Germany; and cDepartment of Neurobiology, University of Eastern Finland, 70211 Kuopio, Finland
Edited by Tony Hunter, The Salk Institute for Biological Studies, La Jolla, CA, and approved May 21, 2012 (received for review February 25, 2012)
Mutations in human leucine-rich-repeat kinase 2 (LRRK2) have been
found to be the most frequent cause of late-onset Parkinson
disease. Here we show that Dictyostelium discoideum Roco4 is
a suitable model to study the structural and biochemical character-
istics of the LRRK2 kinase and can be used for optimization of cur-
rent and identiﬁcation of new LRRK2 inhibitors. We have solved the
structure of Roco4 kinase wild-type, Parkinson disease-related
mutants G1179S and L1180T (G2019S and I2020T in LRRK2) and
the structure of Roco4 kinase in complex with the LRRK2 inhibitor
H1152. Taken together, our datagive important insight in the LRRK2
activation mechanism and, most importantly, explain the G2019S-
related increase in LRRK2 kinase activity.
Leucine-rich-repeat kinase 2 (LRRK2) belongs to the Rocofamily of proteins, which are characterized by the presence of
leucine-rich repeats, a Ras-like G-domain (called “Roc”), a C
terminal of ROC (COR) domain, and a kinase domain (1). Re-
cently, missense mutations in LRRK2 have been linked to auto-
somal-dominant, late-onset Parkinson disease (PD) (2, 3). PD is
a common neurodegenerative disorder characterized by a pro-
gressive loss of dopaminergic neurons of the substantia nigra, as-
sociated with the formation of ﬁbrillar aggregates composed of
α-synuclein and other proteins. PD is characterized clinically by
tremor, bradykinesia, rigidity, and postural instability. The iden-
tiﬁcation of missense mutations in LRRK2 has redeﬁned the role
of genetic variation in PD susceptibility. LRRK2 mutations initi-
ate a penetrant phenotype with complete clinical and neuro-
chemical overlap with idiopathic disease (4–6). The various
mutations that have been identiﬁed in PD are concentrated in the
central region of the protein; one residue mutated in the LRR
region, one in theRoc domain (withmultiple substitutions), one in
the COR domain, and two in the kinase domain (7). The muta-
tions are found in 5–6% of patients with familial PD and, im-
portantly, also have been implicated in sporadic PD (8, 9).
Although much progress has been made during the last few years,
the exact pathogenic role and associated biochemical pathways
responsible for LRRK2-linked disease are emerging only slowly
(10). The multiple disease-linked mutations in LRRK2 repre-
sent a unique opportunity to explore the pathogenicity of
LRRK2 biochemically and to identify therapeutic targets for this
neurodegenerative disorder.
In the absence of suitable amounts of puriﬁed mammalian
LRRK2 protein, and because recombinantly expressed full-length
protein or any fragment thereof turned out to be unstable, insoluble,
or permanently bound to chaperones, structural understanding of
LRRK2 is very limited (11). Therefore, we used related proteins to
investigate the complex structural regulatory mechanism of
LRRK2. Previously we elucidated the structure of the RocCOR
tandem ofChlorobium tepidum, which shows that theRoc domain is
a Ras-like G domain tightly coupled to the COR domain as a di-
merization device. Mutations analogous to Parkinson mutations
were shown to be located in the Roc–COR interface. RocCOR
proteins thus seem to belong to the G proteins activated by the
nucleotide-dependent dimerization (GAD) class of molecular
switches. PD-analogous mutations in Roc and COR alter the Roc–
COR interface and result in decreasedGTPase activity (12, 13). The
structure of the Roc domain of human LRRK2 showed a domain-
swapped dimeric G domain whose signiﬁcance for the native pro-
tein is unclear (11, 13).
LRRK2 kinase activity is linked critically to clinical effects, and
several pathogenic mutations in LRRK2 result in enhanced kinase
activity, suggesting a possible PD-related gain of abnormal or
toxic function (14–16). However, because of the lack of sufﬁcient
recombinant protein and physiological substrate, the published
data regarding kinase activity of the PD-related mutants are
conﬂicting (except for G2019S, which is associated consistently
with an increased kinase activity) (17, 18).
Here we use Dictyostelium discoideum Roco4 as model to study
the structural and biochemical characteristics of the LRRK2 kinase
domain. We have solved the structure of Roco4 kinase wild-type
and PD-relatedmutants G1179S and L1180T (G2019S and I2020T
in LRRK2). A comparison of wild-type and mutant structures
revealed that the PD mutants have different effects and, most
importantly, explains the G2019S-related increase in LRRK2 ki-
nase activity. Identifying small-molecule inhibitors of the kinase
activity that speciﬁcally counteract the effect in vivo will be an
important step towards ﬁnding a treatment for PD. The structure
of Roco4 kinase in complex with the LRRK2 inhibitor H1152
shows that Roco4 is a suitable model system to obtain insight into
the binding mechanism and to optimize current and identify new
LRRK2 inhibitors.
Results and Discussion
Vertebrates possess four Roco proteins, LRRK1, LRRK2,
DAPK1, and MFHAS1. Remarkably, the social amoeba Dictyos-
telium contains 11 Roco family members that contain a large va-
riety of domains and have been studied in detail (19–21). In this
study we used Dictyostelium Roco4, which has the same domain
topology as LRRK2 (Fig. 1A) but is biochemically more tractable.
The kinase domain is well conserved in the Roco family of pro-
teins, and the Roco4 kinase domain (amino acids 1018–1292) has
a similarity of 47% to LRRK2. Unlike LRRK2, the Roco4 kinase
domain could be expressed in Escherichia coli and isolated as
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a soluble and stable protein (Fig. 1B). Dictyostelium are single-
celled amoeba that feed on bacteria. Upon starvation, cells enter
a tightly regulated developmental process, resulting in multicel-
lular fruiting bodies. Dictyostelium cells with a disruption in the
roco4 gene cannot synthesize cellulose, resulting in instable stalks
that are unable to lift the spore head (Fig. 1C) (20). This strong
developmental defect of roco4-nulls cells can be rescued com-
pletely by the expression of wild-typeRoco4 and also by a chimeric
protein of Roco4 in which the kinase domain is replaced by that of
LRRK2 (Fig. 1C). As a further demonstration of the similarity
between the proteins, Roco4 kinase is able to phosphorylate
LRRKtide, an artiﬁcial speciﬁc substrate of LRRK2. Also, Roco4
kinase activity is inhibited by various LRRK2 inhibitors (see be-
low). Taken together, these data show that Roco4 can serve as
model to study the complex regulatory mechanism of LRRK2.
The puriﬁed Roco4 kinase domain (residues 1018–1292) was
found to be autophosphorylated and was additionally incubated
with ATP. It was dephosphorylated by incubation with alkaline
phosphatase. As shown below, phosphorylated Roco4 appears to
be the active form of the protein.
The active, phosphorylated form was crystallized in the presence
of the ATP analog AppCH2p, the dephosphorylated protein
without ATP. The crystals with space group P4(3)3(2)2 had similar
unit cell parameters (42, 42, 340Å) (Table 1). Structures were
solved by molecular replacement using MLK1 (3DTC) as the
search model (Table S1). Roco4 kinase has a canonical kinase fold
with a mostly β-sheet–containing N-terminal lobe and a highly
α-helical C-terminal lobe. The nucleotide is located in the con-
ventional nucleotide-binding site (Fig. 2A). In many kinases, the
activation loop is a highly ﬂexible element and contains the primary
activity-related phosphorylation sites. In the unphosphorylated,
inactive state, this loop often is disordered, but upon phosphory-
lation it reorients into an ordered, active conformation (22, 23). An
overlay of phosphorylatedRoco4 with ERK2, PKA, andDAPK1 in
the active conformations highlights this conservation of the
activation loop conformation (Fig. 2B). Because of its ﬂexibility, the
activation loop is not visible in the structure of dephosphorylated
Roco4, and in the active form only themain chain can be traced. An
overlay of the active and inactive Roco4 structures (shown in cyan
and blue, respectively, in Fig. 2C) shows that the residues E1207/
E1208 (inactive) and V1188, S1189, G1190 (active) would clash,
indicating that the nonresolved loop must be in a different position
in the inactive conformation than in the active conformation
(Fig. 2C).
Phosphorylation of serine and threonine residues in kinase-
activation loops is important for regulating kinase activity in many
protein kinases (22–25). Because the Roco4 kinase becomes
autophosphorylated during kinase assays, it is technically difﬁcult
to measure the difference in kinase activity in the phosphorylated
and dephosphorylated protein. In autophosphorylation assays
Roco4 incorporates maximally 2.04 ± 0.33 mol (n = 5) of
Fig. 1. Dictyostelium Roco4 as model for LRRK2. (A) Domain organization of LRRK2 and Dictyostelium Roco4. (B) Alignment of Roco4 kinase (amino acids
1018–1292) and LRRK2 kinase (amino acids 1879–2138) domains. Conserved residues are shown in red, PD-related mutations are indicated by black asterisks,
the hydrogen bond-accepting residue speciﬁc for PD-related G2019S is indicated by a red asterisk. (C) Phenotype of roco4-null cells and rescue experiments.
roco4-null cells and roco4-null cells expressing Roco4 or Roco4LRRK2 kinase, in which the kinase domain of Roco4 has been replaced with the kinase domain
of LRRK2, were allowed to develop for 48 h on nutrient-free agar. Pieces of agar were excised and photographed from the side.
Table 1. X-ray reﬁnement statistics
Crystal Active Inactive G1179S L1180T H1152
Resolution (Å) 1.8 2.0 2.0 2.3 2.3
Rwork/Rfree 0.19/0.24 0.23/0.26 0.26/0.29 0.25/0.29 0.19/0.23
Number of atoms
Protein 2,208 2,113 2,219 2,207 2,160
Ligand/ion 31 — 46 31 44
Water 211 62 96 165 54
B-factors
Protein 29.9 43.6 26.1 32.8 45.6
Ligand/ion 55.3 — 24.6 70.8 70.3
Water 31.5 30.2 25.7 34.1 31.2
R.m.s deviations
Bond lengths (Å) 0.027 0.007 0.006 0.006 0.024
Bond angles (°) 2.246 0.987 0.956 0.958 1.953








phosphate per mole of protein. Roco4 kinase contains four pu-
tative phosphorylation sites in the activation loop: S1181, S1184,
S1187, and S1189 (Figs. 1B and 2A). To characterize the Roco4
activation mechanism, we reexpressed Roco4 constructs with S-
to-A mutations in roco4-null cells and analyzed them for de-
velopment (Fig. 2D). By reexpressing single mutants and double
mutants, we ﬁnd that the double mutant S1181/1184, but not
S1187/1189, rescues the developmental phenotype. Consistently,
the puriﬁed S1187 and S1189 single mutants and the double
mutant S1187/1189 have hardly any kinase activity, whereas the
double mutant S1181/1184 shows wild-type activity (Fig. S1). The
data show that Roco4 incorporates approximately two moles of
phosphate and that serine 1187 and serine 1189 are essential for
kinase activity. This ﬁnding supports the notion that autophos-
phorylation in the activation loop is required to induce the active
conformation of the kinase.
The putative autophosphorylation sites are not conserved be-
tween Roco4 and LRRK2 (Fig. 1B). LRRK2 contains T2031/
S2032/T2035 (Fig. 1B), three potential phosphorylation sites in
the activation loop. Studies using phosphospeciﬁc antibodies have
shown that all three sites are phosphorylated, but as in Roco4, only
the latter two sites, S2032 and T2035, are important for LRRK2
activity in vivo (26, 27).
PD-linked mutations have been identiﬁed throughout the
LRRK2 gene; one residue is mutated in the LRR region, one in
the Roc domain (with multiple substitutions), one in the COR
domain, and two in the kinase domain (7). The most prevalent PD
mutation is G2019S in the kinase domain, which enhances kinase
activity, whereas the PD-related mutation I2020T shows slightly
decreased activity (15, 16, 28–30). The LRRK2 G2019 and I2020
residues are conserved in Roco4 and correspond to G1179 and
L1180, respectively (Fig. 1B). We have created the corresponding
mutations in Roco4 and determined their biochemical and
structural properties.
Active phosphorylatedRoco4 kinase phosphorylates LRRKtide
with a rate constant of 1.5·103 s−1 (± 427) (Fig. 3A). Like LRRK2,
the Roco4 G1179S mutant showed a 1.5 ± 0.13-fold increased
activity in autophosphorylation, relative to wild-type kinase,
whereas the L1180T mutant shows a slightly but signiﬁcantly de-
creased activity (0.8 ± 0.02) (Fig. 3B). The structures of the Roco
mutants L1180T and G1179S were solved by molecular re-
placement to a resolution of 2.3 and 2.04 Å, respectively. Com-
parison of wild-type and mutant structures did not show large
differences in the overall structure (rmsd 0.6) (Fig. 3C andD). An
overlay of wild-type and themost prevalent PDhomologmutation,
G1179S, revealed an additional hydrogen bond between the mu-
tated S1179 and an R1077 from the regulatory αC-helix, (Fig. 3C,
Fig. 2. (A) Ribbon diagram of Roco4 kinase in the active state
with AppCH2p (red ball and stick model) bound in the nucle-
otide-binding pocket. The activation loop and the regulatory
αC-helix are shown in green and blue, respectively. Relevant
side chains are indicated. In the enlarged view, residues ho-
mologous to relevant PD mutations (in blue/red) and putative
phosphorylation sites within the activation loop (in red) are
highlighted. (B) Overlay of active phosphorylated Roco4 (cyan)
with several kinase structures in the active conformation: ERK2
(2ERK) (green), PKA (2CPK) (orange), and DAPK1 (3GU5) (yel-
low). The enlarged view highlights the activation loops. (C)
Overlay of Roco4 in the active (cyan) and inactive (blue) forms.
The enlarged view highlights the clash of the residues 1207/
1208 (inactive) with 1188–1190 (active). (D) Analysis of Roco4
autophosphorylation sites in vivo. Roco4-null cells expressing
the indicated serine mutants were analyzed for development
as described in Fig. 1C. Pictures were taken from above. Insets
show a side view of a fruiting body. The double-mutant
S1187A/S1189A is not able to rescue the developmental defect
of roco4-null cells.
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Lower Right). We reasoned that this additional hydrogen bond
stabilizes the active conﬁguration involving the DFG motif, the
activation loop, and the αC-helix so that kinase activity is in-
creased. To test our hypothesis, we constructed a double mutant,
G1179S/R1077A, in which the additional hydrogen bond cannot
be formed, and measured kinase activity. Consistent with our
model the G1179S/R1077A mutant has nearly wild-type activity
(0.91 ± 0.02).
We then tested whether the above conclusion holds true for
LRRK2. Roco4 R1077 corresponds to LRRK2 Q1919, but, be-
cause the adjacent R1918 also can form a potential hydrogen bond
with S2019, both were mutated to alanine in wild-type and PD-
mutant LRRK2 (Fig. 1B). Activity of immunoprecipitated LRRK2
was determined by autophosphorylation (Fig. 3B Right and Fig.
S2). Although the R1918A mutation does reduce the activity of
G2019S, R1918A itself has very low activity (Fig. 3B). The Roco4
analog, Q1076, points into the solvent; therefore R1918 is unlikely
to interfere directly with active site conﬁguration (Fig. 3C and Fig.
S3). Dimerization is a common mechanism to regulate kinase ac-
tivity (23). LRRK2, and most likely all Roco proteins, are dimer in
solutions using the COR domain as dimerization interface (12, 13,
27). Autophosphorylation is essential for the function of LRRK2;
however, data for autophosphorylation both in cis and in trans have
been reported (15, 27). The recent structure of Aurora2 shows that
the αC-helix is part of the kinase dimerization interface (31); be-
cause LRRK2 autophosphorylation can occur in trans (15), the
R1918A mutation may disturb the putative dimer interface and
subsequently reduce kinase activity.
As expected, the Q1919A mutation does indeed reduce the
activity of the PD mutant almost to the wild-type level (1.26 ±
0.25) (Fig. 3B) and similar to the level of the Q1919A single mu-
tant (0.87 ± 0.18), indicating that the PD-related increase in
G2019S activity is indeed the result of an additional hydrogen
bond with Q1919, which stabilizes the active conformation.
The structure of the Roco4 PD-homologous mutant L1180T
shows that the T1180 side-chain points into the solvent and most
likely is not involved directly in regulating kinase activity (Fig. 3D).
For LRRK2, it has been postulated that the higher neurotoxicity
of this mutant might be caused by the mutant’s greater suscepti-
bility to intracellular degradation (28, 32). This notion seems
Fig. 3. Structure and properties of PD-related mutants. (A) Roco4-catalyzed phosphorylation of LRRKtide was measured by incubating 3 μM Roco with 150 μM
LRRKtide and 25 μM radioactive ATP. Incorporation of radioactive phosphate was measured as described inMaterial and Methods. The data were ﬁtted to the
equation At = A∞(1-e
−kt). (B) Kinase activity measured by autophosphorylation of wild-type and mutant Roco4 (Left) and wild-type and mutant LRRK2 (Right)
as indicated. For puriﬁed Roco4 kinase, absolute rates are presented. For partially puriﬁed ﬂag-LRRK2, the activity of the mutants is presented relative to the
activity of the wild type. Data shown are the means and SD of at least three independent experiments. *P < 0.001; **P < 0.01 signiﬁcantly different from wild-
type control using ANOVA. (C) Overlay of the ribbon diagrams of the wild-type (cyan) and G1179S mutant Roco4 kinase equivalent to the LRRK2 PD-mutant
G2019S (tan). The enlarged views of wild type (Upper) and G1179S mutant (Lower) reveal that the 1179S mutant has an additional hydrogen bond (red) with
an arginine (blue) of the αC-helix that stabilizes the activation loop. The numbers in brackets give the corresponding numbers in LRRK2. (D) Overlay of the
ribbon diagrams of the wild-type Roco4 kinase (cyan) and the PD-related mutant L1180T (LRRK2 I2020T) (green). Panels on the right represent enlarged views
of the mutational site and show that L1180 (cyan) and T1180 (red) point into the solvent.








unlikely, given that the disease phenotype is autosomal dominant
and caused by a gain of function. Although the Roco4 structure
does not reveal the exact mechanism, we speculate that, in analogy
to the lower activity of B-Raf mutations, which are complemented
by interaction with c-Raf, the kinase domains in LRRK2 work in
tandem so that the interaction between wild-type and LRRK2-
T1180 increases kinase activity (33). More importantly, the data
do show that the PD-related effect of LRRK2 mutations results
from different defects in the LRRK2 activation mechanism and
suggest that the different LRRK2 mutations, such as S2019 and
I2020, might require different methods of inhibition for the pur-
pose of drug development.
To date, several relatively nonspeciﬁc kinase inhibitors, such as
H1152, staurosporine, sunitinib, and GW5074, and more speciﬁc
LRRK2 inhibitors, such as LRRK2-IN-1, have been identiﬁed (34,
35). It is speculated that the ATP-binding site is the direct target
for many of the inhibitors, but the exact binding mechanism is
unknown. We were able to cocrystallize the Roco4 kinase domain
with H1152, which originally was identiﬁed as a rho-associated
protein kinase (ROCK) inhibitor but recently was reported to
have nearly the same inhibitory effect on LRRK2 (35). H1152 also
was found to inhibit Roco4 kinase activity, and binding is ATP
competitive (Fig. 4A). The structure of Roco4 in complex with
H1152 was solved by molecular replacement to a resolution of 2.3
Å and revealed two inhibitor binding sites (Fig. 4B). The ﬁrst
H1152 binding site, is in the nucleotide-binding pocket, as
expected from its inhibitory mechanism, and is similar to themode
in which H1152 binds to ROCK1 (36). The binding site is formed
by 17 residues, and the buried surface area is 280.6 Å2 (Fig. 4C). In
the complex with ROCK1, the H1152 isoquinoline nitrogen
accepts a main-chain hydrogen bond from M156; in Roco4 the
same interaction takes place with V1108 (Fig. 4C). Hydrophobic
interaction of the two H1152 C-4 methyl groups with both Roco4
and ROCK1 helps restrict the conformational freedom of the
inhibitor. The second H1152 binding site is close to the αC-Helix
and is formed by 14 residues in total; 12 are from one kinase
molecule, and two are from a symmetry-related molecule within
the crystal structure (Fig. 4D). The relevance of this second
binding site for inhibition of kinase activity in solution is not clear
but also was observed recently in the H1152 structure in complex
with PKA (37). Roco4 kinase activity is inhibited by H1152 not
only in vitro but also in vivo: Dictyostelium cells in the presence of
0.1 mM and 0.5 mM H1152 have a partial or complete roco4-null
phenotype, respectively (Fig. S4). These results show that Roco4
can be used to characterize LRRK2 inhibitor binding in detail,
biochemically and structurally. Furthermore, Roco4 structures
will allow the construction of a reliable model of LRRK2 for
computer-aided drug development. The biochemical tractability
of Roco4 allows in vitro screening of inhibitor libraries, whereas
the unique phenotype of roco4-null mutants and its rescue by the
Roco4-LRRK2-kinase chimera (Fig. 1C) can be used for in vivo
testing and screening.
Take together our data give important insight into the mecha-
nism of LRRK2 activation and into how a mutation in the kinase
Fig. 4. Binding of the LRRK2-inhibitor H1152 to Roco4. (A) Kinase activity of Roco4 was measured in the presence or absence of the indicated concentration
of H1152 (chemical structure is shown below the plot) in the presence of 25 μM ATP. The results are presented as percentage of kinase activity relative to the
control. (B) Ribbon diagram of Roco4 in complex with H1152. Enlarged views of the two binding sites are shown in the right panels. (C and D) Detailed view of
H1152 binding in the Roco4 nucleotide-binding pocket (C) and in the interface of two molecules in the crystal (D).
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domain increases kinase activity. Although mutants spread over all
parts of the multidomain protein LRRK2 produce a similar path-
ogenic output signal, i.e., PD, our structures show that different
mutations have different defects in the activation mechanism. For
a further understanding of other mutations, it will be important to
characterize fully the intramolecular regulation of LRRK2 and
show how the Roc domain might regulate kinase activity, the role
that COR plays in this process, and how PD-linked missense
mutations alter the interactions between the different domains.
Our work shows that structures of the more tractable Roco4 and
possibly other Roco proteins could be important in this enterprise.
Materials and Methods
Protein Puriﬁcation and Radiometric Assays. Roco4 kinase (amino acids 1018–
1292) was cloned into a Gateway-compatible pGEX4T1 plasmid containing
an N-terminal TEV cleavage side. Proteins were puriﬁed in the presence of
1 mM ATP by GSH afﬁnity, cleavage, and size-exclusion chromatography.
Dephosphorylated Roco4 kinase was obtained by incubating 1 mg isolated
protein with 100 U alkaline phosphate for 1 h at 4 °C. Roco4 kinase activity
was determined at 30 °C in kinase buffer consisting of 20 mM Tris (pH 7.5),
10 mM MgCl2, 1 mM EGTA, 1 mM sodium orthovanadate, 1 mM NaF, 5 mM
β-glycerolphosphate, 0.02% Triton X-100, and 2 mM DTT. Autophosphor-
ylation was measured with 1 mg/mL puriﬁed protein. The reaction was
started by adding 50 μM (2 Ci/mmol) ATP-γ-32P (Perkin-Elmer) and was
stopped by adding 100 mM ice-cold EDTA. Samples were spotted on nitro-
cellulose ﬁlters, washed with 50 mM phosphoric acid, and dried before
scintillation counting (Perkin-Elmer). For LRRKtide, 32P incorporation assays
similar to those described above were performed with 0.05 mg/mL kinase,
25 μM (2 Ci/mmol) ATP-γ-32P, and 150 μM LRRKtide. Kinase inhibition was
determined by varying the concentration of H1152 (Tocris Bioscience). Hu-
man Flag-LRRK2 was expressed and isolated from HEK293T cells by immu-
noprecipitation using anti-Flag (M5) antibody (Sigma), and kinase activity
was measured as previously described (30).
Crystallography. Roco4 crystals were obtained in 100 mM 1,3-bis(tris
(hydroxymethyl)methylamino)propane (pH 8,5), 200 mM Na/K tartrate, and
11% (wt/vol) PEG 3350 using the hanging drop/vapor diffusion method. For
data collection, crystals were cryoprotected in reservoir solution containing
35% (wt/vol) PEG3350 as cryoprotectant. Datasets were collected on beam
line ×10SA at the Swiss Light Source (Paul Scherrer Institut, Villigen, Swit-
zerland) and were indexed, integrated, and scaled with the XDS package
(38). The model was built in COOT (39) and reﬁned with REFMAC5 using TLS-
reﬁnement (CCP4 suite) (40). Figures were generated using PYMOL (DeLano
Scientiﬁc LLC).
Dictyostelium Aggregation Assays. Development of Dictyostelium mutants
was tested as previously described (20). Brieﬂy, cells were harvested in
phosphate buffer (11 mM KH2PO4, 2.8 mM Na2HPO4), plated at a density of
1 × 106 cells/cm2, and allowed to develop for 48 h on nutrient-free plates
containing phosphate buffer supplemented with 15 g/L agar. Pieces of agar
were excised and photographed from the top and side.
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